Treatment effect of breast cancer and prostate cancer on bone

被引：1

作者：

Varsavsky, Mariela ^{[1
]}

Guadalix Iglesias, Sonsoles ^{[2
]}

机构：

[1] Hosp Sant Pau i Santa Tecla, Serv Endocrinol, Tarragona, Spain

[2] Hosp Univ 12 Octubre, Serv Endocrinol, Madrid, Spain

来源：

MEDICINA CLINICA | 2013年 / 140卷 / 04期

关键词：

Breast cancer treatment; Prostate cancer treatment; Bone; Osteoporosis; Aromatase inhibitors; Androgen deprivation therapy; ANDROGEN-DEPRIVATION THERAPY; PLUS ZOLEDRONIC ACID; POSTMENOPAUSAL WOMEN; PRACTICAL GUIDANCE; FOLLOW-UP; MANAGEMENT; OSTEOPOROSIS; MEN; BISPHOSPHONATES; ANASTROZOLE;

D O I：

10.1016/j.medcli.2012.05.025

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aromatase inhibitors are used in the treatment of breast cancer and androgen deprivation therapy is used in prostate cancer. Both of them induce bone loss and increase fracture incidence. Early detection is important for patients with increased risk of osteoporotic fractures. In this article we review the available treatments and their indication to prevent the onset of osteoporosis and osteoporotic fractures in this patient group. (C) 2012 Elsevier Espana, S.L. All rights reserved.

引用

页码：164 / 168

页数：5

共 50 条

[1] Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer
Saad, Fred
Adachi, Jonathan D.
Brown, Jacques P.
Canning, Leah A.
Gelmon, Karen A.
Josse, Robert G.
Pritchard, Kathleen I.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5465 - 5476
[2] Cancer treatment-induced bone loss in patients with breast or prostate cancer
Maxwell, C
Viale, PH
ONCOLOGY NURSING FORUM, 2005, 32 (03) : 589 - 601
[3] Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer
Taxel, Pamela
Faircloth, Erika
Idrees, Sana
Van Poznak, Catherine
JOURNAL OF THE ENDOCRINE SOCIETY, 2018, 2 (07): : 574 - 588
[4] Metabolic bone disease during treatment of breast and prostate cancer
Roux, C
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 3 - 3
[5] Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer
Shunji Takahashi
Journal of Bone and Mineral Metabolism, 2023, 41 : 307 - 316
[6] Management of cancer treatment-induced bone loss (CTIBL) in patients with breast cancer or prostate cancer
Takahashi, Shunji
JOURNAL OF BONE AND MINERAL METABOLISM, 2023, 41 (03) : 307 - 316
[7] Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer
Michaud, Laura Boehnke
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (07) : S20 - S30
[8] Bone loss in patients with breast or prostate cancer
Hu M.I.
Gagel R.F.
Jimenez C.
Current Osteoporosis Reports, 2007, 5 (4) : 170 - 178
[9] Bone loss induced by cancer treatments in breast and prostate cancer patients
Santos Castañeda
Ana Casas
Aránzazu González-del-Alba
Guillermo Martínez-Díaz-Guerra
Xavier Nogués
Cristina Ojeda Thies
Óscar Torregrosa Suau
Álvaro Rodríguez-Lescure
Clinical and Translational Oncology, 2022, 24 : 2090 - 2106
[10] BONE METASTASES IN BREAST-CANCER, PROSTATE-CANCER AND MYELOMA
PATERSON, AHG
BONE, 1987, 8 : S17 - S22

← 1 2 3 4 5 →